Conference Chair

Philippe Carteron de Balmont
CarthaGenetics, Switzerland

Philippe Carteron de Balmont is a highly experienced senior executive in the biotech industry, with over 25 years of experience specifically focused on rare diseases and orphan drugs in the EMEA region. He began his career as a biochemist and lab technician, gaining scientific knowledge that prepared him for roles in the pharmaceutical industry.

In 1992, Philippe entered the  pharma world by working as a sales representative, selling an antibiotic. Later, he then gained experience launching orphan drugs at pioneering companies like Genzyme and TKT 5S Europe, where he demonstrated exceptional skill in establishing patient screening programs, obtaining early access and reimbursement, and building networks of key experts and stakeholders prior European legislation on Orphan drugs, when thinks where only working on the good will of a few people  – He always developed and maintained transparent relationships with patients groups, and national and supranational organization as and Orphanet and Eurordis. Over his career, Philippe has consulted for leading biotech companies including Genzyme, TKT (Shire)  BioMarin, Alexion, Pfizer, Regeneron, Biogen, Ultragenyx, RegenXbio, PTC, and  Alnylam.

He has been instrumental in the pre-launch and launch of major orphan drugs across therapeutic areas like hematology, nephrology, neurology and more. He has negotiated reimbursement and access with health ministries across Europe and the Middle East North Africa (MENA) region. His regulatory and policy development expertise is unmatched, enhancing access to treatment for many f rare disease patients.

In 2004, Philippe founded CarthaGenetics, an orphan drug consultancy company supporting over 25 biotech clients on go-to-market strategy and early access programs. He also established CarthaGenetics subsidiaries across Europe, Turkey and North Africa to serve local needs.

In addition to his 25+ years in industry, Philippe holds an Executive Master in International Negotiation and Policy Making from the Graduate Institute of Geneva, a Pharmaceutical Marketing and Management degree, and certificates in areas like Public Health and Inborn Errors of Metabolism. His diverse education equips him with well-rounded expertise to chair orphan drug congresses.

With his experience launching novel orphan therapies, developing screening infrastructure, navigating policy, and collaborating across borders, Philippe Carteron de Balmont is an ideal leader to chair congresses advancing access to orphan drugs globally.